Stabilizing Neuronal Hyperexcitability to Advance Clinically Translatable Kv7 Therapies for ALS

• Targeting selective Kv7.2/7.3 activation to reduce motor neuron hyperexcitability associated with ALS progression
• Applying electrophysiology and translational biomarkers to improve confidence in CNS ion channel clinical development
• Demonstrating how improved selectivity and brain penetration can support safer chronic dosing in neurodegenerative disease

Speakers:

Dan Elbaum

Chief Scientific Officer

QurAlis Corp.